Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2005-07-05
2005-07-05
Andries, Janet (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S387900, C530S388150, C530S388240, C530S389200, C530S351000
Reexamination Certificate
active
06914128
ABSTRACT:
Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
REFERENCES:
patent: 4816397 (1989-03-01), Boss et al.
patent: 5643768 (1997-07-01), Kawasaki
patent: 5658754 (1997-08-01), Kawasaki
patent: 5780597 (1998-07-01), Gately et al.
patent: 5811523 (1998-09-01), Trinchieri et al.
patent: 6090382 (2000-07-01), Salfeld et al.
patent: 0 659 766 (1995-06-01), None
patent: WO 92/01047 (1992-01-01), None
patent: WO 92/09690 (1992-07-01), None
patent: WO 92/20791 (1992-11-01), None
patent: WO 9404679 (1994-03-01), None
patent: WO 9524918 (1995-09-01), None
patent: WO 97/15327 (1997-05-01), None
patent: WO 99/37682 (1999-07-01), None
patent: WO 02/12500 (2002-02-01), None
Jackson, J.J. et al. “In vitro maturation: improvement of a high affinity, neutralizing antibody against IL-1β.”The Journal of Immunology154(7):3310-19 (1995).
Balashov KE, et al. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci U S A. Jan. 21, 1997;94(2):599-603.
Barbas CF 3rd, et al. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci U S A. Sep. 15, 1991;88(18):7978-82.
Berrebi D, et al. Interleukin-12 expression is focally enhanced in the gastric mucosa of pediatric patients with Crohn's disease. Am J Pathol. Mar. 1998;152(3):667-72.
Bird RE, et al. Single-chain antigen-binding proteins. Science. Oct. 21, 1988;242(4877):423-6.
Brown PS Jr, et al. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival. Proc Natl Acad Sci U S A. Apr. 1, 1991;88(7):2663-7.
Bucht A, et al. Expression of interferon-gamma (IFN-gamma), IL-10, IL-12 and transforming growth factor-beta (TGF-beta) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis (RA). Clin Exp Immunol. Mar. 1996;103(3):357-67.
Carter RW, et al. “Production and characterization of monoclonal antibodies to human interleukin-12,” Hybridoma. Aug. 1997;16(4):363-9.
Clackson T, et al. Making antibody fragments using phage display libraries. Nature. Aug. 15, 1991;352(6336):624-8.
Dall'Acqua W, et al. Antibody engineering. Curr Opin Struct Biol. Aug. 1998;8(4):443-50.
Fais S, et al. Interferon expression in Crohn's disease patients: increased interferon-gamma and -alpha mRNA in the intestinal lamina propria mononuclear cells. J Interferon Res. Oct. 1994;14(5):235-8.
Fuchs P, et al. Targeting recombinant antibodies to the surface ofEscherichia coli: fusion to a peptidoglycan associated lipoprotein. Biotechnology (N Y). Dec. 1991;9(12):1369-72.
Fuss IJ, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. Aug. 1, 1996;157(3):1261-70.
Gately MK, et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol. 1998;16:495-521.
Garrard LJ, et al. Fabassembly and enrichment in a monovalent phage display system. Biotechnology (N Y). Dec. 1991;9(12):1373-7.
Gram H, et al. In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library. Proc Natl Acad Sci U S A. Apr. 15, 1992;89(8):3576-80.
Griffiths AD, et al. Human anti-self antibodies with high specificity from phage display libraries. EMBO J. Feb. 1993;12(2):725-34.
Hanes J, et al. In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci U S A. May 13, 1997;94(10):4937-42.
Hawkins RE, et al. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J Mol Biol. Aug. 5, 1992;226(3):889-96.
Hay BN, et al. Bacteriophage cloning andEscherichia coliexpression of a human IgM Fab. Hum Antibodies Hybridomas. Apr. 1992;3(2):81-5.
Duchmann et al., Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur. J. Immunol. 1996, 26:934-8 (Abstract).
Hoogenboom HR, et al. Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res. Aug. 11, 1991;19(15):4133-7.
He M, et al. Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites. Nucleic Acids Res. Dec. 15, 1997;25(24):4132-4.
Huse WD, et al. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science. Dec. 8, 1989;246(4935):1275-81.
Huston JS, et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inEscherichia coli.Proc Natl Acad Sci U S A. Aug. 1988;85(16):5879-83.
Irving RA, et al. Affinity maturation of recombinant antibodies usingE. colimutator cells, Immunotechnology. Jun. 1996;2(2):127-43.
Junghans RP, et al. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res. Mar. 1, 1990;50(5):1495-502.
Kabat EA, et al. Attempts to locate complementarity-determining residues in the variable positions of light and heavy chains. Ann N Y Acad Sci. Dec. 31, 1971;190:382-93.
Kobayashi M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med. Sep. 1, 1989;170(3):827-45.
Ling P, et al. Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol. Jan. 1, 1995;154(1):116-27.
McCafferty J, et al. Phage antibodies: filamentous phage displaying antibody variable domains. Nature. Dec. 6, 1990;348(6301):552-4.
Monteleone G, et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology. Apr. 1997;112(4):1169-78.
Morita Y, et al. Expression of interleukin-12 in synovial tissue from patients with rheumatoid arthritis. Arthritis Rheum. Feb. 1998;41(2):306-14.
Neurath MF, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. Nov. 1, 1995;182(5):1281-90.
Parronchi P, et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol. Mar. 1997;150(3):823-32.
Pini A, et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis cluted from a two-dimensional gel. J Biol Chem. Aug. 21, 1998;273(34):21769-76.
Pini A, et al. “Hierarchical affinity maturation of a phage library derived antibody for the selective removal of cytomegalovirus from plasma,” J Immunol Methods. Aug. 7, 1997;206(1-2):171-82.
Podlaski FJ, et al. Molecular characterization of interleukin 12. Arch Biochem Biophys. Apr. 1992;294(1):230-7.
Seder RA, et al. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci U S A. Nov. 1, 1993;90(21):10188-92.
Sharon J. Structural correlates of high antibody affinity: three engineered amino acid subst
Banerjee Subhashis
Carmen Sara
Derbyshire Elaine Joy
Du Fou Sarah Leila
Duncan Alexander Robert
Abbott & GmbH & Co. KG
Andries Janet
Hamud Fozia
Hanley Elizabeth A.
Lahive & Cockfield LLP
LandOfFree
Human antibodies that bind human IL-12 and methods for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human antibodies that bind human IL-12 and methods for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human antibodies that bind human IL-12 and methods for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3391798